JonesTrading analyst Justin Walsh initiated coverage of Theratechnologies with a Buy rating and $6 price target. Theratechnologies is a commercial-stage biopharmaceutical company headquartered in Montreal with two approved and marketed drugs in its North America-focused HIV franchise, Walsh tells investors in a research note. The analyst expects growth in the HIV-franchise to support the company’s "increasingly important oncology pipeline." He thinks investors underappreciate the potential of Theratechnologies’ earlier stage development efforts.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on THTX: